ZLZejuan Li

Zejuan Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zejuan Li has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Jianzhong Du

    East China University of Science and Technology

    2 shared publications
  • Shisheng He

    Department of Orthopaedics, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Yanchang Road 301, Shanghai 200072, China

    2 shared publications
  • Xingsen Yang

    Department of Polymeric Materials, School of Materials Science and Engineering, Tongji University, 4800 Caoan Road, Shanghai 201804, China

    2 shared publications
  • Beibei Zhang

    Department of Polymeric Materials, School of Materials Science and Engineering, Tongji University, 4800 Caoan Road, Shanghai 201804, China

    1 shared publication
  • Jianhua Li

    Department of Polymeric Materials, School of Materials Science and Engineering, Tongji University, 4800 Caoan Road, Shanghai 201804, China

    1 shared publication
  • Junhao Liang

    Department of Polymeric Materials, School of Materials Science and Engineering, Tongji University, Shanghai 201804, P. R. China

    1 shared publication

Latest Publications

  • Bone-Targeting Nucleic Acid Delivery Polymer Vector for Effective Therapy of Bone Metastasis

    by Zejuan Li, Xiao Xiao, Xu Pu, Xingsen Yang, Junqiu Shi, Shisheng He, Jianzhong Du, Yunqing Zhu

    Bone diseases, such as bone metastases, pose significant therapeutic challenges due to the distinct physiological environment of skeletal tissues, which complicates the targeted delivery of nucleic acid therapeutics. Existing delivery systems, including lipid nanoparticles (LNP) and polyethylenimine (PEI), struggle to achieve precise bone targeting effectively. To address this issue, we developed a polymer-based bone-targeting bioreducible nucleic acid delivery vector, poly[alendronic acid-co-(N,N'-bis(acryloyl)cystamine-co-4-amino-1-butanol)] (ALN-Pabol), which incorporates alendronic acid (ALN) for precise bone targeting. The ALN-Pabol exhibited a hydroxyapatite binding rate of 91.1%, significantly outperforming nontargeted Pabol/miRNA (73.5%) and commercial systems such as PEI/miRNA (58.3%) and Lipofectamine 2000/miRNA (64.7%). In vivo fluorescence imaging demonstrated its superior skeletal accumulation compared to nontargeted controls. In a murine breast cancer bone metastasis model, ALN-Pabol/miRNA polyplex reduced bone tumor weight by 79.1% relative to PBS controls and 36.8% compared to LNP/miRNA. Mechanistically, the polyplex dissociates in the high-glutathione tumor microenvironment, releasing therapeutic miRNA to suppress cancer cell proliferation and promote apoptosis. Simultaneously, ALN inhibits osteoclast activity, significantly mitigating osteolytic damage. Micro-CT analysis revealed near-complete restoration of bone volume and trabecular architecture to healthy levels. This work establishes ALN-Pabol as a highly promising delivery vector for bone-targeted gene therapy, bridging critical gaps in skeletal disease treatment and expanding potential applications in bone regeneration and cancer therapy.


  • Polyaptamer-Driven Crystallization of Alendronate for Synergistic Osteoporosis Treatment through Osteoclastic Inhibition and Osteogenic Promotion

    by Xingsen Yang, Yu Fan, Junhao Liang, Runfeng Cao, Beibei Zhang, Jianhua Li, Zejuan Li, Shisheng He, Na Liu, Jianzhong Du, et al.

    Osteoclastic inhibition using antiresorptive bisphosphonates and osteogenic promotion using antisclerostin agents represent two distinct osteoporosis treatments in clinical practice, each individual treatment suffers from unsatisfactory therapeutic efficacy due to its indirect intervention in osteoclasis and promotion of osteogenesis simultaneously. Although this issue is anticipated to be resolved by drug synergism, a tempting carrier-free dual-medication nanoassembly remains elusive. Herein, we prepare such a nanoassembly made of antiresorptive alendronate (ALN) crystal and antisclerostin polyaptamer (Apt) via a nucleic acid-driven crystallization method. This nanoparticle can protect Apt from rapid nuclease degradation, avoid the high cytotoxicity of free ALN, and effectively concentrate in the cancellous bone by virtue of the bone-binding ability of DNA and ALN. More importantly, the acid microenvironment of cancellous bone triggers the disassociation of nanoparticles for sustained drug release, from which ALN inhibits the osteoclast-mediated bone resorption while Apt promotes osteogenic differentiation. Our work represents a pioneering demonstration of nucleic acid-driven crystallization of a bisphosphonate into a tempting carrier-free dual-medication nanoassembly. This inaugural advancement augments the antiosteoporosis efficacy through direct inhibition of osteoclasis and promotion of osteogenesis simultaneously and establishes a paradigm for profound understanding of the underlying synergistic antiosteoporosis mechanism of antiresorptive and antisclerostin components. It is envisioned that this study provides a highly generalizable strategy applicable to the tailoring of a diverse array of DNA-inorganic nanocomposites for targeted regulation of intricate pathological niches.